Pharvaris (PHVS) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Pharvaris, a Dutch biopharmaceutical company, has executed the second amendment to its License Agreement with Germany’s BRAIN Biotech AG, effective September 20, 2024. The amendment facilitates the sale of BRAIN Biotech’s revenue rights from Pharvaris to Royalty Pharma and clarifies terms regarding the duration of Pharvaris’s payment obligations. This adjustment reflects an ongoing commitment to managing their intellectual property and financial strategy in the pharmaceutical industry.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
